Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Promotion of healthy gut microbiota" does not refer to a specific molecule, receptor, enzyme, transporter or other canonical therapeutic target. Instead, it describes an overall strategy or goal aimed at supporting the balance and diversity of microorganisms in the gastrointestinal tract. The human gut microbiota comprises bacteria, fungi and viruses that play essential roles in digestion (especially complex carbohydrates), vitamin synthesis (such as B vitamins), immune regulation—including both innate and adaptive responses—and protection against pathogens by competitive exclusion. A diverse and balanced microbial community is associated with resilience against disturbances like antibiotics or infections; reduced diversity has been linked to diseases such as IBD, obesity, type 2 diabetes and cardiovascular disease. Interventions that promote a healthy gut include dietary changes (e.g., increased fiber intake), probiotics/prebiotics supplementation and sometimes fecal transplantation. However—since “promotion” refers to an outcome rather than an actionable molecular entity—it should not be considered a valid therapeutic target per se.[1][2][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Promotion of healthy gut microbiota.